RankAlpha logo
Back to Rankings

REPL

Replimune GroupC
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
A recovery case depends on Replimune producing a credible FDA path for RP1 after the second CRL. The packet still shows a $13.00 median target, but analyst count and post-CRL revision detail are unavailable, so that target should not be treated as fresh confirmation.
Posture
Mixed
Lead driver
Momentum
What changed
2 setup hits (3d) with net bullish as of 2026-06-02.
What can break
Low-coverage small-cap biotech with no fresh analyst revisions in the packet; valuation anchors may be stale after the regulatory setback.
Momentum
97
Value
41
Sentiment
11
Setup hits (3d)
2 · Net Bullish
AI TargetsBase $5.00 · Bull $13.00 · Bear $2.00
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-23 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade C · Mixed
Confidence Medium · Net Bullish
Target $13.00
Why
Momentum97 · Δ7d +21.9
Value41 · Δ7d +0.1
Sentiment11 · Δ7d -50.2
So what
Balanced signals (Net Bullish). Wait for confirmation before sizing up.
Lead driver: Momentum · See technicals
Momentum
97
34% active weight
Current posture
7d trendImproving
Δ7d
+21.9
Δ21d
+95.3
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
11
33% active weight
Current posture
7d trendSoftening
Δ7d
-50.2
Δ21d
-90.1
Why this grade

Composite grade C. Momentum 97.2 / Value 41.1 / Sentiment 10.7

Fundamentals (TTM)
As of 2026-06-01
Market Cap
$743.15M
Beta
0.74
Shares Out
78.44M
P/E (TTM) · Derived
-3.1
P/S (TTM)
-
P/FCF (TTM) · Derived
-3.14
Rev YoY
-
EPS YoY
-33.9%
Gross Margin
-
Op Margin
-
Net Debt
-$411.9M
Current Ratio
6.31
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology